Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic Factors
Chara Stavraka(Guy's Hospital), Athanasios Pouptsis(Guy's and St Thomas' NHS Foundation Trust), Alicja Synowiec(Maidstone Hospital), Vasileios Angelis(Maidstone Hospital), Liyana Satterthwaite, Sam Khan(Leicester Royal Infirmary), Meera Chauhan(Leicester Royal Infirmary), Chloe Holden(Poole Hospital NHS Foundation Trust), Sally Dunaway Young(Poole Hospital NHS Foundation Trust), Christina Karampera(Guy's and St Thomas' NHS Foundation Trust), Maria Martinou(Queen's Hospital), Tina Mills‐Baldock(Queen's Hospital), Mark Baxter(Beatson West of Scotland Cancer Centre), Ainsley Barry(Beatson West of Scotland Cancer Centre), Bryony Eccles(Poole Hospital NHS Foundation Trust), Timothy Iveson(University of Southampton), Kai‐Keen Shiu(University College Hospital), Mark Hill(Maidstone Hospital), Sherif Abdel-Raouf(Queen's Hospital), Janet Graham(Beatson West of Scotland Cancer Centre), Anne Thomas(University of Leicester), Paul J. Ross(Guy's and St Thomas' NHS Foundation Trust)
Cited by 16Open Access
Abstract
Related Papers
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells
Tomohiro Emura, Yuko Murakami, Fumio Nakagawa et al.|International Journal of Molecular Medicine|2004|105